Clinical Trials on Hereditary Retinoblastoma

Total 2640 results

Shire

Completed

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Hereditary Angioedema (HAE)

United States, Germany, Hungary
Shire

Completed

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

Hereditary Angioedema (HAE)

United States, Germany, Spain, Sweden
Shire

Completed

Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

Hereditary Angioedema (HAE)

United States
Shire

Completed

Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

Hereditary Angioedema (HAE)

Israel, Germany, Mexico, United States, Romania
Shire

Completed

A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants

Hereditary Angioedema (HAE)

Japan
Shire

Completed

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

Hereditary Angioedema (HAE)

United States, Jordan, Italy
BioCryst Pharmaceuticals

Completed

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema (APeX-1)

Hereditary Angioedema (HAE)

Canada, United Kingdom, Germany, Spain, Australia, Hungary, Italy, Austria, North Macedonia, Denmark, Switzerland
Edison Pharmaceuticals Inc

No longer available

Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

Leber's Hereditary Optic Neuropathy

United States
Universitaire Ziekenhuizen KU Leuven
Fund for Scientific Research, Flanders, Belgium; Funds for Research in Ophthalmology... and other collaborators

Completed

The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy

Fuchs' Endothelial Dystrophy

Belgium
Takeda

Recruiting

A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada (PROSPECT)

Angioedema | Hereditary Angioedema (HAE)

Canada
Takeda

Recruiting

A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

Hereditary Angioedema (HAE)

United Kingdom
Shire
Takeda Development Center Americas, Inc.

No longer available

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Angioedema | Hereditary Angioedema (HAE)

United States, Canada, Germany, Hungary, Spain
Shire

Completed

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Shire

Completed

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Hereditary Angioedema (HAE)

United States, Canada, Australia, Austria, Colombia, Germany, Hungary, Israel, Italy, Spain
Shire

Completed

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

United States, Canada, Jordan
Shire

Completed

Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

Hereditary Angioedema (HAE)

United States
Shire

Completed

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

Hereditary Angioedema (HAE)

United States
Shire

Completed

Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Shire

Completed

EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema

Hereditary Angioedema (HAE)
Shire
Dyax Corp.

Completed

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

Hereditary Angioedema (HAE)

United States
National Cancer Institute (NCI)

Completed

Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers

Colorectal Neoplasm | Hereditary Nonpolyposis

United States
Chigenovo Co., Ltd

Recruiting

Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Bietti's Crystalline Dystrophy

China
Oregon Health and Science University

Recruiting

OCT in Diagnosis of Irregular Corneas

Corneal Opacity | Keratoconus | Corneal Dystrophy

United States
University Eye Hospital, Freiburg

Completed

Eye Drops for Early Morning-Associated Corneal Swelling of the Cornea (EDEMAS)

Fuchs' Endothelial Dystrophy

Germany
University Hospital, Essen

Completed

Immunmodulation in Patients With HHT

Hereditary Haemorrhagic Telangiectasia (HHT)

Germany
Vaderis Therapeutics AG

Recruiting

Assess Safety and Efficacy of VAD044 in HHT Patients

Hereditary Hemorrhagic Telangiectasia (HHT)

United States, Spain, France, Belgium, Netherlands, Italy
NYU Langone Health
Dyax Corp.

Withdrawn

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

Hereditary Angioedema Types I and II

United States
CSL Behring
Parexel

Completed

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Hereditary Angioedema Types I and II

United States, Germany
CSL Behring

Completed

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

United States, Spain, Germany, Australia, Canada, Czechia, Hungary, Israel, Italy, Romania, United Kingdom
Myriad Genetic Laboratories, Inc.

Completed

Combined Breast Cancer Risk Study

Hereditary Cancer

United States
Stanford University
University of Pennsylvania; University of California, Davis; Oregon Health and... and other collaborators

Recruiting

Descemet Endothelial Thickness Comparison Trial II (DETECT II)

Fuchs' Endothelial Dystrophy | Fuchs Dystrophy | Fuchs

United States
Michael D. Straiko, MD
Lions VisionGift Research; Eye Bank Association of America

Recruiting

Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

Fuchs Endothelial Dystrophy

United States
Trefoil Therapeutics, Inc.

Completed

TTHX1114(NM141) in Combination With DWEK/DSO

Fuchs' Endothelial Dystrophy | Fuchs Dystrophy | Fuchs

United States
University of Illinois at Chicago

Withdrawn

Implementation of Population Breast Cancer Genetic Services in Federally Qualified Health Centers (FQHC) (TestMiGenes)

Hereditary Cancer Syndrome
University of Rochester
Livionex Inc

Completed

A Pilot Study to Assess the Preliminary Efficacy of EDTA Eye Drops on Band Keratopathy

Corneal Dystrophy, Band-Shaped

United States
Centre Hospitalier Universitaire de Besancon

Completed

Long Term Cornea Graft Survival Study (BELIEvE)

Keratoconus | Fuchs' Endothelial Dystrophy

France
University Hospital, Rouen

Completed

Comparison of Two Techniques in Achieving Corneal Graft

Fuch's Endothelial Dystrophy

France
Brigham and Women's Hospital
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Genomic Sequencing for Childhood Risk and Newborn Illness

Genetic Predisposition to Disease | Hereditary Disease

United States
Cornea Research Foundation of America

Withdrawn

Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.

Fuchs' Endothelial Dystrophy

United States
Federal University of São Paulo
Eye Clinic Day Hospital, São Paulo

Unknown

Corneal Transplantation Guided by OCT RESCAN

Keratoconus | Cornea | Bullous Keratopathy | Corneal Dystrophy
University College, London

Recruiting

Hereditary Sensory Neuropathy Serine Trial (SENSE)

Hereditary Sensory Neuropathy Type I

United Kingdom
Beijing Tongren Hospital

Recruiting

Safety Study of rAAV2/8-hCYP4V2 in Patients With Bietti's Crystalline Dystrophy (BCD)

Bietti's Crystalline Dystrophy

China
Marian Macsai, MD

Recruiting

Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

Fuchs' Endothelial Dystrophy

United States
CSL Behring

Completed

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

United States, Spain, Australia, Canada, Czechia, Hungary, Israel, Italy, Romania, United Kingdom
University Hospital, Catania

Unknown

Hereditary AngioEdema, Neurobiology and Psychopathology (HAENP)

Depression | Anxiety | Hereditary AngioEdema

Italy
Shanghai Vitalgen BioPharma Co., Ltd.

Not yet recruiting

Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy

Bietti Crystalline Dystrophy

China
Beijing Tongren Hospital

Recruiting

Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy

Bietti Crystalline Dystrophy

China
Octapharma

Recruiting

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Acute Hereditary Angio Edema

Romania
Hospital Universitari Vall d'Hebron Research Institute
Hospital Universitario La Paz

Not yet recruiting

Identification and Characterization of Genetic Variants in Hereditary Angioedema (GENOMAEH_01)

Hereditary Angioedema With C1 Esterase Inhibitor Deficiency

Spain
First Affiliated Hospital of Fujian Medical University

Recruiting

PCSK9 Inhibitor Treatment for Patients With SPG5

Hereditary Spastic Paraplegia Type 5

China

Clinical Trials on Hereditary Retinoblastoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations